Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23451581 | 0.83 | NOTUM (1.00) | NOTUMKDM4EMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL23452017 | 0.83 | NOTUM (0.71) | NOTUMMAPT | |
| SCHEMBL19211383 | 0.81 | NOTUM (0.68) | NOTUML3MBTL1 | |
| SCHEMBL19211459 | 0.81 | NOTUM (1.00) | NOTUML3MBTL1 | |
| SCHEMBL19211517 | 0.81 | NOTUM (0.68) | NOTUMKDM4EMAPTL3MBTL1 | |
| SCHEMBL17502287 | 0.80 | NOTUM (1.00) | NOTUMKDM4EMAPTL3MBTL1 | |
| SCHEMBL2821461 | 0.80 | NOTUM (1.00) | NOTUMKDM4EMAPTL3MBTL1 | |
| SCHEMBL21792045 | 0.79 | NOTUM (1.00) | NOTUMKDM4EMAPT | |
| SCHEMBL19211410 | 0.79 | NOTUM (0.76) | NOTUMKDM4EMAPT | |
| SCHEMBL19211422 | 0.79 | NOTUM (0.80) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| CN-101018779-A | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | CN | disclosed |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | AATRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1720860-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-26 | — | — | US | disclosed |
| WO-2005080379-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885KDM4E 3907/4885MAPT 1431/4885 |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRIN3A, GRM1 | NOTUM 4056/4885KDM4E 2986/4885MAPT 1892/4885 |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRM3, GRIK5 | NOTUM 4132/4885KDM4E 3314/4885MAPT 1517/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885KDM4E 4149/4885MAPT 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.